EL7.AI
Stocks•16 July 2026•
1 min read

Investor Group Acquires 19.9% Stake in Vivos Therapeutics

Key Facts

1An investor group including V-CO Investors LLC and Michael C. Skaff reported a 19.9% beneficial ownership stake in Vivos Therapeutics.
2The stake consists of 2,783,102 common shares resulting from a $1.6 million subscription and conversion of promissory notes.

In a move highlighting investor interest in micro-cap healthcare firms, an investor group including V-CO Investors LLC and Michael C. Skaff has reported a 19.9% beneficial ownership stake in Vivos Therapeutics. According to reports, the stake comprises 2,783,102 common shares resulting from a $1.6 million subscription and the conversion of promissory notes. This significant position indicates the group's intention to engage with management regarding the company's financial performance and strategic direction.

Vivos Therapeutics (VVOS) operates within the sleep apnea treatment market, positioning itself alongside larger peers such as ResMed and Inspire Medical Systems. While the $1.6 million investment reflects the company's micro-cap status, the nearly 20% stake grants the investor group substantial influence. Per market data, activist-leaning entries in the medical technology sector often signal upcoming pressure for operational improvements or a shift in capital allocation strategies to enhance shareholder value.

Investors should monitor broader macro signals, including the U.S. Monetary Policy Report scheduled for July 10, 2026, and a speech by Fed Governor Bowman on July 13, 2026, as these events will shape the financing environment for small-cap medical innovation companies.